

Functional Healing with Synergy

BP-DES

Aloke Finn, MD
CVPath Institute Inc.
Gaithersburg, MD
University of Maryland
Baltimore, MD



PCI EVOLUTION
Continuous
improvement in
platform design
and acute
performance

1977

- POBA: **Getting** Artery Open

1986

- BMS: **Keeping** Artery Open

2003

- DES Decrease **Restenosis**


2015+

- Future DES: Optimize **Healing**

- Lower late events rates – ST, TLR
- Reduced need for prolonged DAPT
- Reduced risk of neoatherosclerosis

Event rates persist beyond 1 year with current PERMANENT Polymer DES-Why?

Resolute All Comers 5-year TLF




No. at risk

Resolute	1140	1110	1035	992	960	920
Xience V	1152	1122	1031	995	959	926


TLF (target Lesion Failure) is defined as cardiac death, TVMI, of clinically driven TLR.

Frequency of the single or highest-ranked (most plausible) mechanism of very late stent thrombosis in the 58 analyzed stents




Masanori Taniwaki et al. *Circulation*. 2016;133:650-660

Incidence and Timing of Atherosclerotic Change




Progression of Neatherosclerosis


Foamy macrophage clusters




Fibroatheroma, early and late




Late Fibroatheroma with a large NC




Late Fibroatheroma with hemorrhage



Thin-cap Fibroatheroma




In-stent plaque rupture




Neatherosclerosis was defined as the presence of foamy macrophages within the neointima with or without necrotic core and/or calcification.


Cumulative incidence of Neoatherosclerosis(%)



Foamy macrophage
Xience (5 years)




Fibroatheroma
Cypher (5 years)



Rupture
Vision (5 years)

%



Causes of Neoatherosclerosis: Impact of Vascular Healing





What is Complete Vessel healing?



Delayed Healing

- Peristrut fibrin deposition
- Few Smooth muscle cells – peristrut and above the strut
- Incomplete endothelialization


Complete Healing

- No fibrin deposition
- Smooth muscle cells, proteoglycans & collagen – above the strut
- **Complete and functional endothelium**







Antithrombotic and Prothrombotic Factors in Endothelial cells




Importance of the Endothelial Function in Health and Disease

- The endothelium plays a critical role in vascular homeostasis by providing a solid barrier between blood and vessel wall, secreting substances that not only acutely regulate vascular tone, platelet activity, and coagulation factors but also influence vascular inflammation, cell migration, and proliferation over the longer term
- Dysfunction of the endothelium is the initial inciting event in atherogenesis
- VE-cadherin regulates endothelial barrier function via binding to p120 (red arrow). Impaired endothelial barrier function because of dissociation of VE-cadherin and p120 interaction (blue arrow)
- Unhealthy endothelium has dysregulation of these two molecules which normally should be expressed together at endothelial cell borders




mTOR inhibitors and the endothelium

- Sirolimus inhibits mTOR complex by binding FKBP12.6 and displaces it from intracellular calcium release channels
- Sirolimus/FKBP12.6 increases intracellular calcium levels and endothelial dysfunction by PKC activation
- VE-cadherin regulates endothelial barrier function via binding to p120. PKC α activation causes impaired endothelial barrier function via disruption of the VE-cadherin and p120 interaction
- Limiting exposure to sirolimus through biodegradable polymers may improve endothelial function more quickly




Endothelial permeability can be measured using Evans Blue, a dye which binds highly to albumin and stains areas of vascular permeability blue when infused intravenously

BMS vs Durable Polymer DES at 60 Days Following Evans Blue Dye












Evans Blue Analysis of Endothelial permeability





VE-CAD / p120 Co-localization – at 60 days

BMS

DP-DES



VE-CAD Pattern and Monocyte Adhesion



DP-DES

Atherosclerosis Rabbit Model

Stent Implantation
Ileofemoral Artery



100 Days Normal Diet

N=6

Evans Blue
Injection

Explantation




30d Pulse



Baseline cholesterol level 29 ± 18
Final cholesterol level 273 ± 98





High Cholesterol



Neoatherosclerosis model at 130 days

BMS



DP-EES



VECAD RAM11 DAPI

VE-Cad/P120


RAM11 area



Endothelial Function in biodegradable polymer Synergy DES


SYNERGY vs PROMUS Element

In Vivo Release and Pharmacokinetic Analysis





SYNERGY and PROMUS Element stents were implanted into up to three coronary arteries (RCA, LCX, and LAD) of uninjured, domestic, Yorkshire cross swine (N=134 swine). Stents were explanted at pre-determined time points up to 120 days. Everolimus remaining on the explanted stents was extracted and arterial everolimus concentration was analyzed using HPLC/MS.

Experiment design Rabbit Model




BMS vs. BP-DES at 28-days in rabbit model




BMS

Synergy


VE-cad




Evans Blue Area (%)



120 Days REBEL



120 Days Synergy



Do Bioabsorbable Polymer Synergy offer an advantage over durable polymers?

Conclusions:

- Bioabsorbable polymers have an important advantage over durable polymers.
- Endothelial barrier function is impaired in durable polymer DES for long period of time (?how long) as compared to BMS. These cells are more prone to neoatherosclerosis as shown in our enriched cholesterol fed rabbit model.
- In biodegradable polymer Synergy, endothelium function was comparable to BMS at 120 days, a timepoint by which polymer had degraded.
- Further studies are needed to demonstrate a definite advantage for Synergy over durable polymer DES
 - Neoatherosclerosis model
 - Profiling of dysfunctional endothelial cells
- Such findings are impossible to show in humans at the current time but should result in lower long-term events

Acknowledgments

Funding

CVPath Institute Inc.

CVPath Institute

Hiro Yoshi Mori, MD
Emanuel Harari, MD
Sho Torii, MD
Hiroyuki Jinnouchi, MD
Elena Ladich, MD
Robert Kutz, MS
Ed Acampado, DVM
Youhui Liang, MD
Abebe Atiso, HT
Jinky Beyer
Lila Adams, HT
Frank D Kolodgie, PhD
Liang Guo, PhD
Aloke V. Finn, MD

